Document is current
Any future updates will be listed below
-
Authors
Meneghetti, Asier Rabasco
Hernández, Marta Ligero
Kühn, Jens-Peter
Löck, Steffen
Carrero, Zunamys Itzell
Perez-Lopez, Raquel
Bressem, Keno K.
Brinker, Titus J.
Pearson, Alexander T.
Truhn, Daniel
Nebelung, Sven
Kather, Jakob Nikolas
-
Funding
Funding for this research was provided by:
Horizon Europe and Innovation Programme (101079894, 101057091)
Bundesministerium für Bildung und Forschung (031L0312A, 01KD2104C)
Deutsche Forschungsgemeinschaft (TR 1700/7-1)
HORIZON EUROPE European Research Council (GA 101057091, 101114631)
Deutsche Krebshilfe (70115166)
Deutscher Akademischer Austauschdienst,Germany (57616814)
Gemeinsamer Bundesausschuss (01VSF21048)
National Institutes of Health (R01 CA263318)
National Institute for Health and Care Research (NIHR203331)
Technische Universität Dresden
- License Information
-
More Information
Article History
Received: 4 April 2025
Accepted: 20 May 2025
First Online: 24 June 2025
Declarations
:
: Ethics approval was given by the Ethical Committee of the Technische Universität Dresden under the ethics number BO-EK-444102022. Patient consent was deemed unnecessary due to the public nature of the datasets. Clinical trial number: not applicable.
: Not applicable.
: DT received honoraria for lectures by Bayer, GE, and Philips and holds shares in StratifAI GmbH, Germany and in Synagen GmbH, Germany. JNK declares consulting services for Bioptimus, France; Panakeia, UK; AstraZeneca, UK; and MultiplexDx, Slovakia. Furthermore, he holds shares in StratifAI, Germany, Synagen, Germany, Ignition Lab, Germany; has received an institutional research grant by GSK; and has received honoraria by AstraZeneca, Bayer, Daiichi Sankyo, Eisai, Janssen, Merck, MSD, BMS, Roche, Pfizer, and Fresenius.
